Biography of Shane Schaffer

Shane Schaffer is the co-founder, chairman, and chief executive officer of Cingulate Therapeutics in Kansas City, Kansas. In Phase 3 clinical-stage development, this company focuses on creating and managing several branded, next-generation pharmaceutical products. Notably engaged in addressing Attention Deficit/Hyperactivity Disorders (ADHD), it also covers other therapeutic areas such as anxiety disorders and insomnia.

With a 25-year track record in the pharmaceutical industry, he specializes in drug development and commercialization. His effective leadership and entrepreneurial approach in product

launches, brand planning, joint venture brand management, life cycle management, and market development have made him a prominent figure in biopharmaceutical and marketing.

Educational Background

He completed his doctoral degree in Pharmacy at the University of Kansas in 1999 He furthered his education with a post-doctoral pharmaceutical industry fellowship at Rutgers University's College of Pharmacy During his fellowship, he worked for Pfizer Worldwide Marketing and Morris Plains

At Pfizer Worldwide Marketing in New York, he served as a Marketing Manager, where he collaboratively developed pre-launch strategies and initiated the Global Communications Intranet to enhance communication between medical and marketing stakeholders. He also played a role in creating and implementing Pfizer's Medical and Academic Partnership in Pain Management.

He was appointed Project Manager and External Research Manager in Morris Plains, New Jersey. He led advanced sales training and managed development as a Product Launch Trainer for femhrt® He also oversaw the initiation of Phase IV Medical Research across all marketed brands

Career Achievements

Throughout his career, Shane Schaffer has held various managerial roles at Pfizer, Novartis, and Sanofi including their predecessor companies At Novartis, he embraced his passion for the pharmaceutical industry by managing the Ritalin® LA / Focalin™ segments as a Product Manager, significantly advancing Novartis' ADHD franchise

He launched Ritalin® LA in 2002, achieving 166% of the planned budget, and Focalin™ with 114% attainment These medications, designed to treat ADHD, quickly gained 90% product awareness due to his innovative strategies His multiple product launches earned him the Novartis Business Excellence Award.

In 2004, he spearheaded all operations of the ADHD franchise, initiating a faculty development program that trained over 1,400 speakers in three months. His outstanding market and consumer engagement efforts were recognized with the PREMIER Award from the Neuroscience Sales Organization and multiple Novartis Ovation "Above and Beyond" Awards.

Contributions to Sanofi-Aventis

Post-Novartis, he continued his impactful work at Sanofi Aventis and its predecessor companies His roles included leadership, development, and strategy implementation for Avapro and Avalide in a joint venture with Bristol-Myers Squibb. He was deeply involved in Professional Promotion and aged Care Marketing Strategy and executed Salesforce strategies

He also contributed significantly to the promotional campaigns for Avalide, developing and managing all aspects of the campaign From 2004 to 2005, he was a Senior Marketing Manager for Hyalgan, Eligard, and Arixtra, where he not only strengthened professional relationships but also managed promotion and contract strategies, leading to 94% budget attainment and earning him the Sanofi Star Award for three consecutive years

After leaving Sanofi-Aventis, he joined M|C Communications LLC in Boston as a Consultant, overseeing the development of business opportunities and managing operations for over a dozen primary pharmaceutical targets. In July 2009, he founded Sabre Scientific Solutions, LLC, providing significant consulting services across the commercial, clinical, LCM, product launch, and leadership sectors

Cingulate Therapeutics LLC

Driven by his passion for ADHD and its treatment, Shane founded Cingulate Therapeutics LLC in January 2013 His vast experience has been pivotal in steering the company towards innovative drug delivery technologies for ADHD and anxiety disorders.

Cingulate has partnered with Indegene to market its oral ADHD drug, CTx-1301, which has entered Phase 3 trials. This partnership aims to revolutionize the way ADHD drugs are delivered, potentially reducing dependency on prescribed medications

Philanthropic Contributions

Beyond his professional life, Shane Schaffer is committed to philanthropic efforts, mainly through his work with Folds of Honor Charity, which provides scholarships and educational opportunities to children impacted by the loss or disability of a military parent His dedication extends beyond his business achievements, reflecting his deep commitment to societal contributions and educational support